Something I don't quite understand yet...
A company is going to implant tissue derived from embryonic stem cells. Even under best conditions, that tissue will be foreign to the host, just like a kidney or liver transplant. So,
a) How much immunosuppression would be needed? A little? A lot?
b) What kinds of immunosuppressants would be used? Cyclosporin? Tacrolimus? Others?
c) Has anyone explored whether immunosuppressants are toxic to the implants? Some immunosuppressants used in kidney transplants are nephrotoxic. This may be a kidney-specific issue, but I think it's a question worth asking.
d) Would you just accept the fact that the tissue will be rejected, and re-transplant later?
Comments welcome...
Companies & Industry
Reliance Life Sciences (RLS), the pioneer of embryonic stem cell research in the country, is likely to launch its first stem cell-based therapies for neuro-degenerated diseases, including Parkinson’s and ocular diseases and spinal cord injury soon. Considering the successful completion of the pre-clinical and clinical studies with due regulatory approval in another six months to one year period, these novel therapies are likely to be launched in the country by the end of next year, sources from the company said.
Comments